• 제목/요약/키워드: Multicenter

검색결과 370건 처리시간 0.023초

외국인과 내국인 산모 출생아의 비교 연구 (Comparative study of newborns of Asian immigrant and Korean women)

  • 박희옥;임재우;진현승;심재원;김민희;김천수;김은령;김승연;박상기;이정주
    • Clinical and Experimental Pediatrics
    • /
    • 제52권10호
    • /
    • pp.1119-1126
    • /
    • 2009
  • 목 적 : 현재 내국인 남자와 외국인 여자와의 국제 결혼이 크게 증가하고 있으며 이에 따라 이들 사이에 출생하는 신생아의 수도증가하고 있다. 저자들은 아시아계 개발 도상권의 외국인 산모에서 출생한 신생아가 내국인 산모에게서 출생한 신생아에 비하여 어떠한 차이가 있는지 알아보고자 본 연구를 시행하였다. 방 법 : 2005년 1월부터 2008년 6월까지 국내 9개 병원에서 출생한 신생아 중 아시아계 개발 도상권 외국인 산모에서 태어난 333명을 대상으로 하였고, 무작위로 선택한 같은 출생년도, 성별과 재태 주령을 가진 내국인 산모에서 태어난 333명을 대조군으로 하였다. 이들 신생아의 의무기록을 기초로 산모의 국적, 나이, 과거력을 파악하였고, 신생아의 선천성 감염 여부와 신생아의 체중, 키, 두위를 통한 성장 상태와 유병률, 아프가 점수등을 후향적으로 조사하여 양 군을 비교하였다. 결 과 : 전체 18,840명 중 외국인 산모 출생아는 407명(2.1%)이었고 전체 미숙아 수는 5,061명(26.8%)이며 외국인 산모에서 출생한 미숙아는 85명(20.8%), 출생과 동시에 입원한 환아 수는 전체 8,577 (45.5%)이었고 이중 외국인 산모 출생아는 127명(31.2%)이었다. 외국인 산모군에서 산모 국적은 필리핀 69명, 베트남 141명, 중국 51명, 몽고 50명이었으며 기타 우즈베키스탄, 태국 등이 22명이었다. 외국인 산모군의 신생아는 남아 177명, 여아 156명으로 평균 출생체중은 $2,869.1{\pm}685.3gm$이었고, 대조군은 남아 177명, 여아 156명이며 출생체중은 $2,995.1{\pm}689.8gm$으로 외국인 산모군이 유의하게 작았다(P<0.05). 분만 당시 산모의 연령은 외국인 산모군이 $26.7{\pm}5.7$세, 대조군이 $30.8{\pm}4.1$세로 유의한 차이가 있었고(P<0.05), 산모 과거력의 차이는 없었으나 선천 매독 빈도는 외국인 산모군에서 유의하게 높았다(P<0.05). 그 외에 출생 시 두위, 신장, 유병률 및 사망률, 1분 및 5분 아프가 점수는 두 군간에 유의한 차이는 없었다. 결 론 : 아시아계 개발 도상권 외국인 산모에게 태어난 신생아는 내국인 산모 출생아에 비하여 선천 매독 감염의 빈도가 유의하게 높았고, 분만시 산모의 연령이 유의하게 적었으며 신생아의 체중이 유의하게 작았다. 하지만 산모의 과거력, 출생 직후 상태 및 신장, 두위, 유병률은 두 군간의 유의한 차이가 없었고 부당 경량아 및 자궁내 발육지연의 빈도 역시 차이가 없었다.

골 이식술 후 Osstem Implant (US II Plus/GS II)의 다기관 임상연구 (A multicenter clinical study of installed US II Plus/GS II Osstem implants after bone graft)

  • 정광;오철중;하지원;국민석;박홍주;오희균;김수관;김영균;김우철
    • 대한치과의사협회지
    • /
    • 제50권12호
    • /
    • pp.743-754
    • /
    • 2012
  • urpose : The purpose of this study was to evaluate the US II plus/GS II Osstem$^{(R)}$ implants through the study for the clinical success rate during the installation of the Osstem¢Á implants after bone graft. Materials and Methods : This study was researched in the 4 medical institutions: Chonnam National University, Chosun University, Bundang Seoul National University Hospital, and FM dental clinic from May, 2002 to September, 2009. Based on the total number of 60 patients whose treatment was the installation of the US II plus/GS II Osstem¢Á implants after bone graft, we evaluated success rate of implants. We analysis the distribution of patient's age and gender, edentulous area, bone type, fixture length and diameter, installation and loading time, donor site, bone graft material and method, antagonistic teeth, and survival and success rate. From these analyses we got the following results. Results : 1. In this study, the total number of patients who have been installed with US II plus implant was 27, and total of 52 implants were installed. The average age was 38.9, with 16 male, and 11 female patients. 2. The total number of patients who have been installed with GS II implant was 33, and total of 54 implants were installed. The average age was 49.7, with 24 male, and 9 female patients. 3. As for bone graft method, either autogenous bone or a mix of autogenous and heterogenous bone was used(88.4%) for US II plus. Chin, iliac, and Maxillary tuberosity were the donor sites for autogenous bone graft, and onlay method of bone graft was performed. 4. Allogenic bone or a mix of autogenous and heterogenous bone was used(77.8%) for GS II. Chin, ramus, and tibia were the donor sites for autogenous bone graft, and GBR method of bone graft was performed. 5. The duration from the installation of implants to setting of final prosthesis was average of 16 months and 10 months for US II plus and GS II respectively. Also, the final follow up period was average of 31 months and 28 months respectively. During this period, one GS II implant was removed from 1 patient due to failure of early osteointegration. 6. The survival rates were 100% and 98.1%, and success rates were 94.2% and 94.4% for US II plus and GS II implant respectively. Conclusion : On the evaluation of our clinical study, both US II plus and GS II Osstem¢Á implants showed the excellent clinical results after bone graft.

키토산 함유 치약의 임상적 효과;Multicenter study (Clinical Efficacy of Toothpaste Containing Chitosan;Multicenter study)

  • 김민경;최성호;신승윤;류인철;허익;박준봉;조규성
    • Journal of Periodontal and Implant Science
    • /
    • 제33권2호
    • /
    • pp.167-178
    • /
    • 2003
  • Many researches are being done to study the effect of toothpaste containing natural extracts. The aim of this study was to evaluate the plaque control effect and therapeutic effect of toothpaste products containing chitosan extract. 120 healthy subjects with gingivitis or early periodontitis were divided into two groups. Subjects in the experimental group only used toothpaste containing chitosan and subjects in the control group used toothpaste without chitosan. At first, subjects received scaling and tooth brushing instruction. Gingival index, bleeding index, probing pocket depth, probing attachment level were scored at baseline, 2 months, and 3 months, and plaque index were scored at baseline, 1 month, 2 months, 3 months. Gingival index of experimental group and control group at baseline, 2 months, and 3 months use were 0.71${\pm}$0.66, 0.49${\pm}$0.55, 0.36${\pm}$0.49 and 0.62${\pm}$0.58, 0.51${\pm}$0.52, 0.48${\pm}$0.50 (mean${\pm}$SD), respectively (statistically significant different at p <0.05 ). Plaque index of experimental group and control group at baseline, 1 month, 2 months, and 3 months were 0.52${\pm}$0.50, 0.43${\pm}$0.50, 0.39${\pm}$0.49, 0.29${\pm}$0.46 and 0.49${\pm}$0.50, 0.50${\pm}$0.50, 0.51${\pm}$0.50, 0.45${\pm}$0.50, respectively (statistically significant different at p<0.05 ). Bleeding index of experimental group and control group were 0.40${\pm}$0.49, 0.33${\pm}$0.47, 0.24${\pm}$0.43 and 0.40${\pm}$0.49,0,38${\pm}$0.49,0.30${\pm}$0.46, respectively (statistically significant different at p<0.05). Probing depth of experimental group and control group were 2.41${\pm}$0.64, 2.31${\pm}$0.60, 2.28${\pm}$0.55 and 2.51${\pm}$0.67, 2.47${\pm}$0.63,2.42${\pm}$0.62, respectively (statistically significant different at p${\pm}$0.66, 2.32${\pm}$0.62 and 2.54${\pm}$0.70, 2.51${\pm}$0.69,2.46${\pm}$0.66, respectively (statistically significant different at p<0.05 ). From these finding, it can be concluded that toothpaste containing chitosan have better plaque control effect and therapeutic effect on gingivitis and early periodontitis compared to conventional toothpastes.

Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts

  • Kang, Ben;Kim, Jung Eun;Jung, Jae Hun;Choe, Jae Young;Kim, Mi Jin;Choe, Yon Ho;Kim, Seung;Koh, Hong;Lee, Yoo Min;Lee, Jee Hyun;Lee, Yoon;Lee, Ji-Hyuk;Lee, Hae Jeong;Jang, Hyo-Jeong;Choi, Youjin;Choi, So Yoon;Kim, Ju Young;Choe, Byung-Ho
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제23권1호
    • /
    • pp.49-62
    • /
    • 2020
  • Purpose: We aimed to investigate the disease phenotype of Korean pediatric Crohn's disease (CD) patients at diagnosis according to the Paris classification by comparison with patients from the European multicenter 5-years recruitment of children with newly developed IBD (EUROKIDS registry). Methods: Korean children and adolescents who had been newly diagnosed with CD at the age of <18 years during 2013-2016 were included in this multicenter retrospective study. Disease phenotype at diagnosis was classified according to the Paris classification, and compared with the published data from the EUROKIDS study. Results: A total of 255 patients were included. The median diagnosis age was 14.7 years (range, 0.8-17.9 years). No significant difference was observed in male-to-female ratio with EUROKIDS (1.9:1 vs. 1.45:1, p=0.062). The proportion of children aged <10 years was significantly lower in Koreans (7.1% vs. 19.6%, p<0.001). Colonic disease was less prominent (10.0% vs. 27.3%, p<0.001), while upper GI involvement was more prominent in Korean children (59.3% vs. 46.2%, p<0.001). The proportion with perianal fistulizing disease at diagnosis was significantly higher in Korean patients (44.8% vs. 8.2%, p<0.001). A separate analysis of Korean patients revealed that perianal fistulizing disease at diagnosis was positively associated with male sex and body mass index z-score (odds ratio [OR]=2.12, 95% confidence interval [CI]=1.20-3.76, p=0.010; and OR=1.29, 95% CI=1.05-1.58, p=0.015, respectively). Conclusion: Approximately half of pediatric CD patients in Korea present with perianal fistulas and/or abscesses at diagnosis, which is a distinct feature of CD in Korean children and adolescents compared to their European counterparts. An underlying genetic difference between ethnicities may play a role in this expression of different phenotypes in pediatric CD.

방사선 치료 중인 두경부 종양 환자를 대상으로 메게이스 내복 현탁액 경구투여 후 유효성 및 안전성에 관한 다기관, 공개, 관측연구 (Multicenter, Open-Labeled, Observational Clinical Trial to Investigate the Efficacy and Safety of Oral Administration of Megace Suspension in Patients with Head and Neck Cancer During Radiotherapy)

  • 김세헌;김민식;김영모;김현수;남순열;노영수;박영학;백정환;봉정표;이강대;이용섭;정광윤;정성민;정필상;주영훈;주형로;최은창;태경;홍기환
    • 대한두경부종양학회지
    • /
    • 제24권1호
    • /
    • pp.57-63
    • /
    • 2008
  • Background and Purpose:Nausea, vomiting and weight loss are common problems that are encountered in the course of cancer patient treatment who are receiving radiotherapy. In this study, we are aiming to analyze the effect of megestrol acetate on quality of life of head and neck cancer patients receiving radiotherapy, resulting from improvement of weight loss, appetite and nutritional status via multicenter, open-labeled, observational clinical trial. Material and Methods:A total of 270 patients from 10 medical institutes who are receiving radiotherapy or who have completed radiotherapy within 3 months, between February 2007 and February 2008, were selected as candidates for the study. Megestrol acetate suspension(megace) was given to the subjectives once a week for 4 weeks with the amount of 20ml(megestrol 800mg). Measurement of weight and questionnaire surveys were carried out three times: at the start of the study, 4 weeks after the start of the medication, and 4 weeks after the end of the medication, respectively. Results:The group who has received megace had a total number of 199, and control group was 70. The group who have received megace showed mean weight loss of 1kg in 8 weeks, compared with the weight loss of 5.5kg in control group, which showed that the medication was effective in reducing the amount of weight loss(P=0.027). The group who received megace had a tendency to report a reduced rate of decrease in the score of appetite, nausea and vomiting, and QOL score, but it did not have statistical significance(P>0.05). Conclusion:Megestrol acetate have reduced the degree of weight loss significantly, and it has a tendency to reduce the rate of decrease in appetite, aggravation of nausea and vomiting, and quality of life.

Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea

  • Song, Jason Jungsik;Song, Yeong Wook;Bae, Sang Cheol;Cha, Hoon-Suk;Choe, Jung-Yoon;Choi, Sung Jae;Kim, Hyun Ah;Kim, Jinseok;Kim, Sung-Soo;Lee, Choong-Ki;Lee, Jisoo;Lee, Sang-Heon;Lee, Shin-Seok;Lee, Soo-Kon;Lee, Sung Won;Park, Sung-Hwan;Park, Won;Shim, Seung Cheol;Suh, Chang-Hee;Yoo, Bin;Yoo, Dae-Hyun;Yoo, Wan-Hee
    • Journal of Korean Medical Science
    • /
    • 제33권52호
    • /
    • pp.346.1-346.11
    • /
    • 2018
  • Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for Asian patients with early rheumatoid arthritis (RA) in Korea. Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were recruited from 20 institutions across Korea and stratified into 2 groups, depending on whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T group) or by rheumatologists who provided usual care (non-T2T group). Data regarding demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire (KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, the prescription for disease-modifying antirheumatic drugs was tailored to the predefined treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity (LDA) ($2.6{\leq}DAS28$ < 3.2). Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA or remission, 59.5% vs. 35.8%; P < 0.001; remission, 43.6% vs. 19.8%; P < 0.001). Compared with non-T2T, T2T was also associated with higher rate of good European League Against Rheumatism response (63.0% vs. 39.8%; P < 0.001), improved KHAQ scores (-0.38 vs. -0.13; P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001). Conclusion: In Asian patients with early RA, T2T improves disease activity and physical function. Setting a pre-defined treatment target in terms of DAS28 is recommended.

다기관 코호트 연구에서 경동맥 내막-중막 두께 측정의 측정자간 신뢰도 평가 (Inter-Rater Reliability of Carotid Intima-Media Thickness Measurements in a Multicenter Cohort Study)

  • Lee, Jung Hyun;Choi, Dong Phil;Shim, Jee-Seon;Kim, Dae Jung;Park, Sung-Ha;Kim, Hyeon Chang
    • Journal of health informatics and statistics
    • /
    • 제41권1호
    • /
    • pp.49-56
    • /
    • 2016
  • 목적: 경동맥 내막-중막 두께와 경동맥 경화반의 존재유무는 죽상동맥경화증의 임상 전단계를 나타내는 지표로 널리 사용되고 있다. 경동맥 내막-중막 두께를 측정할 때의 측정자 의존성 때문에, 다기관 연구에서는 경동맥 내막-중막 두께와 경화반 측정의 기관간 신뢰도를 확인하는 것이 중요하다. 이 연구의 목적은 심뇌혈관 및 대사질환원인 연구센터에 속해 있는 세 임상기관 사이의 경동맥 내막-중막 두께와 경화반 측정의 측정자간 신뢰도를 평가하는 것이다. 방법: 심뇌혈관 질환 과거력이 없는 사람 20명이 2014-2015년 사이에 이 연구에 참여하였고(연령 37-64세), 미리 정해진 프로토콜에 따라 연구참여자의 좌, 우 경동맥을 세 임상기관에서 반복적으로 측정하였다. 총 경동맥의 원위부에서 측정한 경동맥 내막-중막 두께의 최대값과 평균값을 기록하였다. 경동맥에서의 경화반 존재유무는 측정자에 의해 확인되었다. 경동맥 내막-중막 두께와 경화반 존재유무의 신뢰도를 급내상관계수와 카파 통계량을 통해 각각 평가하였다. 결과: 계산된 급내상관계수는 최대 경동맥 내막-중막 두께를 평가하였을 때 0.647이었고 (95% CI: 0.487-0.779), 평균 경동맥 내막-중막 두께를 평가하였을 때 0.758 (95% CI: 0.632-0.854) 이었다. Bland Altman plot에서, 관측치의 대부분은 평균의 차이에서 ${\pm}1.96$ 표준편차 사이에 분포하였다. 각 기관 사이의 경화반 존재유무에 대한 카파 통계량은 0.304 (기관 1과 2), 0.507 (기관 1과 3), 0.606 (기관 2와 3)이었다. 전반적인 일치를 평가하는 Fleiss카파값은 0.445였다. 결론: 세 임상기관 사이의 경동맥 내막-중막 두께의 측정자간 신뢰도는 훌륭하였으며, 경화반 존재유무에 대한 신뢰도는 적정하였다.

A Multicenter Study to Identify the Respiratory Pathogens Associated with Exacerbation of Chronic Obstructive Pulmonary Disease in Korea

  • Lee, Hyun Woo;Sim, Yun Su;Jung, Ji Ye;Seo, Hyewon;Park, Jeong-Woong;Min, Kyung Hoon;Lee, Jae Ha;Kim, Byung-Keun;Lee, Myung Goo;Oh, Yeon-Mok;Ra, Seung Won;Kim, Tae-Hyung;Hwang, Yong Il;Rhee, Chin Kook;Joo, Hyonsoo;Lee, Eung Gu;Lee, Jin Hwa;Park, Hye Yun;Kim, Woo Jin;Um, Soo-Jung;Choi, Joon Young;Lee, Chang-Hoon;An, Tai Joon;Park, Yeonhee;Yoon, Young-Soon;Park, Joo Hun;Yoo, Kwang Ha;Kim, Deog Kyeom
    • Tuberculosis and Respiratory Diseases
    • /
    • 제85권1호
    • /
    • pp.37-46
    • /
    • 2022
  • Background: Although respiratory tract infection is one of the most important factors triggering acute exacerbation of chronic obstructive pulmonary disease (AE-COPD), limited data are available to suggest an epidemiologic pattern of microbiology in South Korea. Methods: A multicenter observational study was conducted between January 2015 and December 2018 across 28 hospitals in South Korea. Adult patients with moderate-to-severe acute exacerbations of COPD were eligible to participate in the present study. The participants underwent all conventional tests to identify etiology of microbial pathogenesis. The primary outcome was the percentage of different microbiological pathogens causing AE-COPD. A comparative microbiological analysis of the patients with overlapping asthma-COPD (ACO) and pure COPD was performed. Results: We included 1,186 patients with AE-COPD. Patients with pure COPD constituted 87.9% and those with ACO accounted for 12.1%. Nearly half of the patients used an inhaled corticosteroid-containing regimen and one-fifth used systemic corticosteroids. Respiratory pathogens were found in 55.3% of all such patients. Bacteria and viruses were detected in 33% and 33.2%, respectively. Bacterial and viral coinfections were found in 10.9%. The most frequently detected bacteria were Pseudomonas aeruginosa (9.8%), and the most frequently detected virus was influenza A (10.4%). Multiple bacterial infections were more likely to appear in ACO than in pure COPD (8.3% vs. 3.6%, p=0.016). Conclusion: Distinct microbiological patterns were identified in patients with moderate-to-severe AE-COPD in South Korea. These findings may improve evidence-based management of patients with AE-COPD and represent the basis for further studies investigating infectious pathogens in patients with COPD.

First-Pass Recanalization with EmboTrap II in Acute Ischemic Stroke (FREE-AIS): A Multicenter Prospective Study

  • Jang-Hyun Baek;Byung Moon Kim;Sang Hyun Suh;Hong-Jun Jeon;Eun Hyun Ihm;Hyungjong Park;Chang-Hyun Kim;Sang-Hoon Cha;Chi-Hoon Choi;Kyung Sik Yi;Jun-Hwee Kim;Sangil Suh;Byungjun Kim;Yoonkyung Chang;So Yeon Kim;Jae Sang Oh;Ji Hoe Heo;Dong Joon Kim;Hyo Suk Nam;Young Dae Kim
    • Korean Journal of Radiology
    • /
    • 제24권2호
    • /
    • pp.145-154
    • /
    • 2023
  • Objective: We aimed to evaluate the efficacy of EmboTrap II in terms of first-pass recanalization and to determine whether it could yield favorable outcomes. Materials and Methods: In this multicenter, prospective study, we consecutively enrolled patients who underwent mechanical thrombectomy using EmboTrap II as a front-line device. The primary outcome was the first pass effect (FPE) rate defined by modified Thrombolysis In Cerebral Infarction (mTICI) grade 2c or 3 by the first pass of EmboTrap II. In addition, modified FPE (mFPE; mTICI grade 2b-3 by the first pass of EmboTrap II), successful recanalization (final mTICI grade 2b-3), and clinical outcomes were assessed. We also analyzed the effect of FPE on a modified Rankin Scale (mRS) score of 0-2 at 3 months. Results: Two hundred-ten patients (mean age ± standard deviation, 73.3 ± 11.4 years; male, 55.7%) were included. Ninety-nine patients (47.1%) had FPE, and mFPE was achieved in 150 (71.4%) patients. Successful recanalization was achieved in 191 (91.0%) patients. Among them, 164 (85.9%) patients underwent successful recanalization by exclusively using EmboTrap II. The time from groin puncture to FPE was 25.0 minutes (interquartile range, 17.0-35.0 minutes). Procedure-related complications were observed in seven (3.3%) patients. Symptomatic intracranial hemorrhage developed in 14 (6.7%) patients. One hundred twenty-three (58.9% of 209 completely followed) patients had an mRS score of 0-2. Sixteen (7.7% of 209) patients died during the follow-up period. Patients who had successful recanalization with FPE were four times more likely to have an mRS score of 0-2 than those who had successful recanalization without FPE (adjusted odds ratio, 4.13; 95% confidence interval, 1.59-10.8; p = 0.004). Conclusion: Mechanical thrombectomy using the front-line EmboTrap II is effective and safe. In particular, FPE rates were high. Achieving FPE was important for an mRS score of 0-2, even in patients with successful recanalization.

한국인의 만성 기관지염의 급성 악화 환자를 대상으로 한 Moxifloxacin 400mg 1 일 1회 요법과 Clarithromycin 500mg 1일 2회 요법의 치료효과 및 안전성 비교 (A Multicenter, Randomized, Open, Comparative Study for the Efficacy and Safety of Oral Moxifloxacin 400 mg Once a Day and Clarithromycin 500 mg Twice Daily in Korean Patients with Acute Exacerbations of Chronic Bronchitis)

  • 김승준;김석찬;이숙영;윤형규;김태연;김영균;송정섭;박성학;김호중;정만표;서지영;권오정;이신형;강경호;이이형;황성철;한명호
    • Tuberculosis and Respiratory Diseases
    • /
    • 제49권6호
    • /
    • pp.740-751
    • /
    • 2000
  • 연구배경 : Moxifloxacin은 광범위한 미생물에 대한 뛰어난 효과, 안전한profile과 유리한 약물동력을 바탕으로 기존의 fluoroquinolones보다 한단계 진보된 약물이라고 할 수 있다. 이러한 효과는 베타-락탐계 혹은 기타 항생제에 내성을 보이는 미생물들에 대해 매우 유효하다. Moxifloxacin은 특히 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella spp. 그리고 Mycoplasma pneumoniae에 의해 유발되는 호흡기 감염에 특히 유용하다고 알려져 있다. 방법 : 다기관, 무작위, 공개, 비교시험으로 만성기관지염의 급성악화 환자를 대상으로 moxifloxacin 400 mg 1일 1회 7일 투여와 clarithromycin 500 mg 1일 2회 7일 투여 그룹간의 안전성과 유효성을 비교하였다. 결과 : 170명의 환자 중에서 87명이 moxifloxacin 투여군 이었고 83명이 clarithromycin 투여군이었다. Moxifloxacin 투여군종에서 76명(세균학적 효과분석은 35명), clarithromycin 투여군중에서 77명(세균학적 효과분석은 31명)이 치료효과분석에 포함되었으며 모든 환자에서 안전성을 분석하였다. 임상적 성공율은 Moxifloxacin 투여군 76명중에서 70명(92.1%) 이었고 clarithromycin 투여군 77명중에서 71명(92.2%) 으로 유사하였다. 세균학적 Moxifloxacin 투여군이 73.5%, clarithromycin 투여군이 54.8% 으로 Moxifloxacin 투여군에서 높게 나타났으나 통계적으로 유의한 차이는 보이지 않았다(p=0.098). 내원시 시행한 객담의 세균 감수성 검사에서 moxifloxacin 투여군이 clarithromycin 투여군보다 Streptococcus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae에서 높은 감수성을 보여주었다(p<0.001). 이상반응은 moxifloxacin 투여군 86명중에서 12.8% 에서 나타났고, clarithromycin 투여군 83명중에서 21.7%에서 발생하였다. 두통(4.7% vs 4.8%, 각각 moxifloxacin 투여군 vs clarithromycin 투여군)과 소화불량(2.3% vs 6.0%, 각각 moxifloxacin투여군 vs clarithromycin 투여군) 이 두 군에서 가장 흔한 이상 반응이었다. 결론 : 본 임상시혐의 결과, 만성기관지염의 급성악화 환자의 치료에 있어서 moxifloxacin 400 mg 1일 1회 7일간 요법은 clarithromycin 500 mg 1일 2회 요법과 비교할 때 임상적으로 동등한 결과를 나타냈으며 미생물학적으로 우월한 결과를 보여주었다.

  • PDF